This means that passive immunization with tau antibodies is actually a viable therapeutic target and which the CSF amount of p-tau262/356 or of your microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to watch tau therapeutics in medical trials. Their story laid the i